Limited inhibition of multiple nodes in a driver network blocks metastasis

Author:

Yesilkanal Ali Ekrem1ORCID,Yang Dongbo1,Valdespino Andrea1,Tiwari Payal1,Sabino Alan U2ORCID,Nguyen Long Chi1,Lee Jiyoung1ORCID,Xie Xiao-He1,Sun Siqi1,Dann Christopher1,Robinson-Mailman Lydia1,Steinberg Ethan1,Stuhlmiller Timothy3,Frankenberger Casey1,Goldsmith Elizabeth4,Johnson Gary L3ORCID,Ramos Alexandre F2,Rosner Marsha R1ORCID

Affiliation:

1. Ben May Department for Cancer Research, University of Chicago, Chicago, United States

2. Instituto do Câncer do Estado de São Paulo, Faculdade de Medicina and Escola de Artes, Ciências e Humanidades; University of São Paulo, São Paulo, Brazil

3. Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, United States

4. UT Southwestern, Dallas, United States

Abstract

Metastasis suppression by high-dose, multi-drug targeting is unsuccessful due to network heterogeneity and compensatory network activation. Here, we show that targeting driver network signaling capacity by limited inhibition of core pathways is a more effective anti-metastatic strategy. This principle underlies the action of a physiological metastasis suppressor, Raf Kinase Inhibitory Protein (RKIP), that moderately decreases stress-regulated MAP kinase network activity, reducing output to transcription factors such as pro-metastastic BACH1 and motility-related target genes. We developed a low-dose four-drug mimic that blocks metastatic colonization in mouse breast cancer models and increases survival. Experiments and network flow modeling show limited inhibition of multiple pathways is required to overcome variation in MAPK network topology and suppress signaling output across heterogeneous tumor cells. Restricting inhibition of individual kinases dissipates surplus signal, preventing threshold activation of compensatory kinase networks. This low-dose multi-drug approach to decrease signaling capacity of driver networks represents a transformative, clinically relevant strategy for anti-metastatic treatment.

Funder

National Institutes of Health

University of Chicago

University of Sao Paulo

University of São Paulo

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior

Publisher

eLife Sciences Publications, Ltd

Subject

General Immunology and Microbiology,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3